REYON News
Total 39
![The AAV gene therapy, under co-development of Reyon Pharmaceutical and Neuracle Genetics, has received approval for phase 1/2a clinical trials in Canada](/webfile/board/0/746/20230607135949_1_20230503_크롭.png)
The AAV gene therapy, under co-development of Reyon Pharmaceutical and Neuracle Genetics, has received approval for phase 1/2a clinical trials in Canada
2023.05.02
![Reyon Pharmaceutical signed a joint development agreement with Therabest for NK cell therapy](/webfile/board/0/745/20230607135709_1_첨부2.-양사-대표이사-계약체결식-사진_thumb_230503.jpg)
Reyon Pharmaceutical signed a joint development agreement with Therabest for NK cell therapy
2023.04.11
![Reyon Pharmaceutical signed an MOU with Connext for comprehensive business cooperation in the CDMO business](/webfile/board/0/744/20230607135451_1_첨부2.-양사-대표이사-MOU-체결식-사진_thumb.jpg)
Reyon Pharmaceutical signed an MOU with Connext for comprehensive business cooperation in the CDMO business
2022.12.14
![Reyon Pharmaceutical signed an MOU with Protium Science for comprehensive business cooperation for CDMO business](/webfile/board/0/742/20230607134748_1_첨부2.-양사-대표이사-MOU-체결식-사진_thumb.jpg)
Reyon Pharmaceutical signed an MOU with Protium Science for comprehensive business cooperation for CDMO business
2022.12.06
![](/webfile/board/0/743/20230607135210_1_20221124_크롭.png)
Reyon Pharmaceutical signed an MOU with Therabest for business cooperation to supply pDNA samples
2022.11.24
![Reyon Pharmaceutical signed an MOU with T&R Biofab for the joint development and commercialization of next-generation hemostatic agents](/webfile/board/0/741/20230607134331_1_20211029111251_1_이연제약뉴스_크롭.png)
Reyon Pharmaceutical signed an MOU with T&R Biofab for the joint development and commercialization of next-generation hemostatic agents
2022.10.25
![Reyon Pharmaceutical and Neuracle Science discuss launching follow-up clinical trials for new antibody drugs against neurodegenerative diseases](/webfile/board/0/740/20230607133733_1_20211029111251_1_이연제약뉴스_크롭.png)
Reyon Pharmaceutical and Neuracle Science discuss launching follow-up clinical trials for new antibody drugs against neurodegenerative diseases
2022.10.24
![A GMP clinical-grade gene-therapy mass production system by Reyon Pharmaceutical and Samsung Seoul Hospital is selected as a national project](/webfile/board/0/739/20230607133018_1_20220926140438_1_썸네일.jpg)
A GMP clinical-grade gene-therapy mass production system by Reyon Pharmaceutical and Samsung Seoul Hospital is selected as a national project
2022.09.23
![Reyon Pharmaceutical participates in Bioplus-Interpex Korea 2022 for partnership expansion.](/webfile/board/0/738/20230607132434_1_첨부2. 이연제약 부스 사진-3.jpg)
Reyon Pharmaceutical participates in Bioplus-Interpex Korea 2022 for partnership expansion
2022.08.03
![Reyon Pharmaceutical signed an MOU with Aston Science for joint R&D and commercializing a plasmid-DNA cancer treatment vaccine](/webfile/board/0/736/20230605182040_1_첨부2.-애스톤사이언스-이연제약-MOU-사진_thumb.jpg)
Reyon Pharmaceutical signed an MOU with Aston Science for joint R&D and commercializing a plasmid-DNA cancer treatment vaccine
2022.06.09